Preliminary Study on the Development of Nanoemulsions for Carbamazepine Intravenous Delivery: An Investigation of Drug Polymorphic Transition

REFERENCES

• Akkar A., Müller R. H. Formulation of intravenous carbamazepine emulsions by SolEmuls® technology. Eur. J. Pharm. Biopharm. 2003; 55: 305–312
   PubMed Web of Science ®Google Scholar
• Becirevic-Lacan M., Jug M., Bacic-Vrca V., Cetina-Cizmek B. Development of o/w emulsion formulation for carbamazepine by using modified cyclodextrins. Acta Pharm. 2002; 52: 149–159
   Google Scholar
• Benita S., Levy M. Y. Submicron emulsions as colloidal drug carriers for intravenous administration: Comprehensive physicochemical characterization. J. Pharm. Sci. 1993; 82: 1069–1079
   PubMed Web of Science ®Google Scholar
• Bouchemal K., Briançon S., Perrier E., Fessi H. Nano-emulsion formulation using spontaneous emulsification: Solvent, oil and surfactant optimization. Int. J. Pharm., 280: 241–251
   PubMed Web of Science ®Google Scholar
• Brewster M. E., Anderson W. R., Estes K. S., Bodor N. Development of aqueous parenteral formulations for carbamazepine through the use of modified cyclodextrins. J. Pharm. Sci., 80: 380–383
   PubMed Web of Science ®Google Scholar
• http://www.fda.gov/cder/ob/default.htm Food and Drug Administration. (2006). Orange book: Approved drug products with therapeutic equivalence evaluations (24th ed.). Retrieved, from Food and Drug Administration Web site accessed
   Google Scholar
• Remington: The pharmaceutical sciences and qractice of pharmacy, A. R. Genaro. Lippincott Williams & Wilkins, Philadelphia 2000
   Google Scholar
• Goodman L. S., Gilman A. G., Hardman J. G., Limbird L. E. Goodman & Gilman's the pharmacological basis of therapeutics. McGraw-Hill, New York 2001
   Google Scholar
• Gosselin P. M., Thibert R., Preda M., Mcmullen J. N. Polymorphic properties of micronized carbamazepine produced by RESS. Int. J. Pharm. 2003; 252: 225–233
   PubMed Web of Science ®Google Scholar
• Han J., Suryanarayanan R. Applications of pressure differential scanning calorimetry in the study of pharmaceutical hydrates: I. Carbamazepine dihydrate. Int. J. Pharm. 1997; 157: 209–218
   PubMed Web of Science ®Google Scholar
• Kaneniwa N., Ichikawa J., Yamaguchi T., Hayashi K., Watari N., Sumi M. Dissolution behaviour of carbamazepine polymorphs. Yakugaku Zasshi. 1987; 107: 808–813
   PubMed Web of Science ®Google Scholar
• Kaneniwa N., Yamaguchi T., Watari N., Otsuka M. Hygroscopicity of carbamazepine crystalline powders. Yakugaku Zasshi 1984; 104: 184–190
   PubMed Web of Science ®Google Scholar
• Kobayashi Y., Ito S., Itai S., Yamamoto K. Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate. Int. J. Pharm. 2000; 193: 137–146
   PubMed Web of Science ®Google Scholar
• Koester L. S., Mayorga P., Pereira V. P., Petzhold C. L., Bassani V. L. Carbamazepine/BCD/HPMC solid dispersions. II. Physical characterization. Drug Dev. Ind. Pharm. 2003; 29: 145–154
   PubMed Web of Science ®Google Scholar
• Krahn F. U., Mielck J. B. Relations between several polymorphic forms and the dihydrate of carbamazepine. Pharm. Acta. Helv. 1987; 62: 247–254
   PubMedGoogle Scholar
• Levy R. H., Lockard J. S., Green J. R., Friel P., Martis L. Pharmacokinetics of carbamazepine in monkeys following intravenous and oral administration. J. Pharm. Sci. 1975; 64: 302–307
   PubMed Web of Science ®Google Scholar
• Loscher W., Honack D., Richter A., Schulz H. U., Schurer M., Dusing R., et al. New injectable aqueous carbamazepine solution through complexing with 2-hydroxypropyl-beta-cyclodextrin: Tolerability and pharmacokinetics after intravenous injection in comparison to a glycofurol-based formulation. Epilepsia 1995; 36: 255–261
   PubMed Web of Science ®Google Scholar
• Lowes M. M. J., Caira M. R., Lotter A. P., Vanderwatt J. G. Physicochemical properties and X-ray structural studies of the trigonal polymorph of carbamazepine. J. Pharm. Sci. 1987; 76: 744–752
   PubMed Web of Science ®Google Scholar
• Luhtala S. Effect of sodium lauryl sulphate and polysorbate 80 on crystal growth and aqueous solubility of carbamazepine. Acta Pharm. Nord. 1992; 4: 85–89
   Google Scholar
• Murphy D., Rodríguez-Cintrón F., Langevin B., Kelly R. C. Rodríguez-Hornedo, N. Solution-mediated phase transformation of anhydrous to dihydrate carbamazepine and the effect of lattice disorder. Int. J Pharm. 2002; 246: 121–134
   PubMed Web of Science ®Google Scholar
• Nair R., Gonen S., Hoag S. W. Influence of polyethylene glycol and povidone on the polymorphic transformation and solubility of carbamazepine. Int. J. Pharm. 2002; 240: 11–22
   PubMed Web of Science ®Google Scholar
• Otsuka M., Ofusa T., Matsuda T. Effect of environmental humidity on the transformation pathway of carbamazepine polymorphic modifications during grinding. Coll. Surf. B. 1999; 13: 263–273
   Web of Science ®Google Scholar
• Otsuka M., Ofusa T., Matsuda T. Effect of binders on polymorphic transformation kinetics of carbamazepine in aqueous solution. Coll. Surf. B. 2000; 17: 145–152
   Web of Science ®Google Scholar
• Phadnis N., Cavatur R. K., Suryanarayanan R. Identification of drugs in pharmaceutical dosage forms by X-ray powder diffractometry. J. Pharm. Biom. Anal. 1997; 15: 929–943
   PubMed Web of Science ®Google Scholar
• Reffner J. A., Seelenbinder J. A., Tobler C. H. Advances in infrared microprobe instrumentation: Integration of image analysis and molecular spectroscopy. Microsc. Microanal. 2005; 11(2)796–797
   Google Scholar
• Rustichelli C., Gamberini G., Ferioli V., Gamberini M. C., Ficarra R., Tommasini S. Solid-state study of polymorphic drugs: Carbamazepine. J. Pharm. Biomed. Anal. 2000; 23: 41–54
   PubMed Web of Science ®Google Scholar
• Martindale: The complete drug reference, S. C. Sweetman. Pharmaceutical Press, LondonUK 2006
   Google Scholar
• Sznitowska M., Janicki S., Dabrowska E., Zurowska-Pryczkowska K. Submicron emulsions as drug carriers: Studies on destabilization potential of various drugs. Eur. J. Pharm. Sci. 2001; 12: 175–179
   PubMed Web of Science ®Google Scholar
• Tauboll E., Lindström S., Klem W., Gjerstad L. A new injectable carbamazepine solution—Antiepileptic effects and pharmaceutical properties. Epilepsy Res. 1990; 7: 59–64
   PubMed Web of Science ®Google Scholar
• Tian F., Sandler N., Gordon K.C., McGoverin C.M., Reay A., Strachan C.J., et al. Visualizing the conversion of carbamazepine in aqueous suspension with and without the presence of excipients: A single crystal study using SEM and Raman microscopy. Eur. J. Pharm. Biopharm. 2006b; 64: 326–335
   PubMed Web of Science ®Google Scholar
• Tian F., Zeitler J.A., Strachan C.J., Saville D.J., Gordon K.C., Rades T. Characterizing the conversion kinetics of carbamazepine polymorphs to the dihydrate in aqueous suspension using Raman spectroscopy. J. Pharm. Biomed. Anal. 2006a; 40: 271–280
   PubMed Web of Science ®Google Scholar
• United States Pharmacopeia. United States pharmacopeia–national formulary (USP28/NF23). United States Pharmacopeial Convention, Rockville 2005
   Google Scholar
• Yu W., Tabosa Do Egito E. S., Barrat G., Fessi J.P., Devissaguet J.P., Puisieux F. A novel approach to the preparation of injectable emulsions by spontaneous emulsification process. Int. J. Pharm 1993; 89: 139–146
   Web of Science ®Google Scholar